Douglas Virostko, MD
Family Medicine · Coshocton, OHNPI 1538164868
Payments from drug & device makers
Across 291 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$672
- Novo Nordisk$477
- GSK$403
- Lilly USA, LLC$335
- Corcept Therapeutics$325
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,106100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $1,382 |
| AbbVie(2 entities) | 48 | $672 |
| Novo Nordisk | 45 | $477 |
| GSK | 31 | $403 |
| Lilly USA, LLC | 27 | $335 |
| Corcept Therapeutics | 17 | $325 |
| Boehringer Ingelheim | 17 | $262 |
| Johnson & Johnson | 10 | $175 |
| Pfizer | 7 | $105 |
| Boston Scientific | 3 | $101 |
| Astellas Pharma US Inc | 4 | $90 |
| Mylan Specialty L.p. | 4 | $90 |
| Amgen | 5 | $76 |
| Exact Sciences | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Merck | 4 | $54 |
| Bayer | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Lundbeck LLC | 1 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Monaghan Medical Corporation | 1 | $22 |
| Northgate Technologies, Inc. | 1 | $22 |
| Vertex | 1 | $19 |
| Novartis | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Abiomed | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
| Cranial Technologies, Inc | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,118 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $146,328 |
| JardianceEmpagliflozin | 120 | $125,555 |
| EliquisApixaban | 114 | $110,990 |
| TrulicityDulaglutide | 69 | $97,779 |
| FarxigaDapagliflozin Propanediol | 47 | $57,347 |
| JanuviaSitagliptin Phosphate | 47 | $53,780 |
| XareltoRivaroxaban | 38 | $39,363 |
| LinzessLinaclotide | 28 | $19,754 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,663 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $16,468 |
| MounjaroTirzepatide | 14 | $15,803 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,316 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,271 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $6,995 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $6,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $262 | $151,339153 claims |
| Novo NordiskOzempic | $477 | $146,328133 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $335 | $113,58183 claims |
| PfizerEliquis | $105 | $110,990114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,382 | $66,61858 claims |
| MerckJanuvia | $54 | $53,78047 claims |
| Johnson & JohnsonXarelto | $175 | $39,36338 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $403 | $24,65844 claims |
| AbbVieLinzess | $672 | $19,75428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Coshocton
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.